EVMN
Evommune, Inc.
NYSE: EVMN · HEALTHCARE · BIOTECHNOLOGY
$23.80
-0.21% today
Updated 2026-04-30
Market cap
$914.15M
P/E ratio
—
P/S ratio
70.32x
EPS (TTM)
$-11.22
Dividend yield
—
52W range
$14 – $33
Volume
0.3M
Evommune, Inc. (EVMN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $5.00M | $7.00M | $13.00M |
| Revenue growth (YoY) | — | +40.0% | +85.7% |
| Cost of revenue | $1.00M | $1.29M | $1.39M |
| Gross profit | $4.00M | $5.71M | $11.61M |
| Gross margin | 80.0% | 81.6% | 89.3% |
| R&D | $32.00M | $64.24M | $74.04M |
| SG&A | — | — | $20.03M |
| Operating income | $-37.85M | $-70.01M | $-81.07M |
| Operating margin | -757.0% | -1000.2% | -623.6% |
| EBITDA | $-32.99M | $-65.49M | $-79.68M |
| EBITDA margin | -659.9% | -935.5% | -612.9% |
| EBIT | $-33.99M | $-66.77M | $-81.07M |
| Interest expense | $58000.00 | $34000.00 | $7000.00 |
| Income tax | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% |
| Net income | $-34.05M | $-66.81M | $-68.87M |
| Net income growth (YoY) | — | -96.2% | -3.1% |
| Profit margin | -681.1% | -954.4% | -529.8% |